MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat

BACKGROUND: Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with an appalling overall survival of less than 5% (Zimmerman et al. J Thor Oncol 14:768-83, 2019). Patients typically respond to front line platinum-based doublet chemotherapy, but almost universally relapse with drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jasmine, Guanizo, Aleks C., Jakasekara, W. Samantha N., Inampudi, Chaitanya, Luong, Quinton, Garama, Daniel J., Alamgeer, Muhammad, Thakur, Nishant, DeVeer, Michael, Ganju, Vinod, Watkins, D. Neil, Cain, Jason E., Gough, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131464/
https://www.ncbi.nlm.nih.gov/pubmed/37098540
http://dx.doi.org/10.1186/s13046-023-02678-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131464/
https://www.ncbi.nlm.nih.gov/pubmed/37098540
http://dx.doi.org/10.1186/s13046-023-02678-1

Ejemplares similares